<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03439462</url>
  </required_header>
  <id_info>
    <org_study_id>COLO-007</org_study_id>
    <nct_id>NCT03439462</nct_id>
  </id_info>
  <brief_title>ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aadi, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aadi, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with&#xD;
      mFOLFOX6 and Bevacizumab as first-line therapy in patients with advanced or metastatic&#xD;
      colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS at 6 months</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median PFS</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009; nab-rapamycin; albumin-bound rapamycin</intervention_name>
    <description>albumin-bound rapamycin</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologically confirmed advanced or metastatic colorectal cancers for&#xD;
             whom chemotherapy is indicated.&#xD;
&#xD;
          2. Patients must not have had prior chemotherapy for advanced or metastatic disease.&#xD;
             Patients could have received adjuvant chemotherapy or adjuvant chemo-radiotherapy.&#xD;
&#xD;
          3. Patients must have at least 1 measurable site of disease according to RECIST v1.1 that&#xD;
             has not been previously irradiated. If the patient has had previous radiation to the&#xD;
             marker lesion(s), there must be radiological evidence of progression since the&#xD;
             radiation.&#xD;
&#xD;
          4. Eligible patients, 18 years or older, with Eastern Cooperative Oncology Group (ECOG)&#xD;
             performance status 0, 1, or 2.&#xD;
&#xD;
          5. Patients must not have been previously treated with an mTOR inhibitor.&#xD;
&#xD;
          6. Adequate liver function:&#xD;
&#xD;
               1. Total bilirubin ≤1.5 x upper limit of normal (ULN) mg/dL&#xD;
&#xD;
               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN&#xD;
                  (&lt;5 x ULN if the patient has liver metastases).&#xD;
&#xD;
          7. Adequate renal function:&#xD;
&#xD;
             a. Serum creatinine ≤2 x ULN or creatinine clearance &gt;50 cc/hr (Cockroft-Gault).&#xD;
&#xD;
          8. Adequate biological parameters:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L&#xD;
&#xD;
               2. Platelet count ≥100,000/mm3 (100 × 109/L)&#xD;
&#xD;
               3. Hemoglobin ≥9 g/dL.&#xD;
&#xD;
          9. Fasting serum triglyceride ≤300 mg/dL; fasting serum cholesterol ≤350 mg/dL.&#xD;
&#xD;
         10. INR and PTT &lt;1.5 x ULN (anticoagulation is allowed if target INR &lt;1.5 on a stable dose&#xD;
             of warfarin or on a stable dose of LMW heparin for &gt;2 weeks at time of enrollment).&#xD;
&#xD;
         11. Minimum of 4 weeks since any major surgery, completion of radiation, or completion of&#xD;
             all prior systemic anticancer therapy, and ≥6 months since adjuvant FOLFOX therapy&#xD;
             (adequately recovered from the acute toxicities of any prior therapy, including&#xD;
             neuropathy should be grade ≤1).&#xD;
&#xD;
         12. Male or non-pregnant and non-breast feeding female:&#xD;
&#xD;
               -  Females of child-bearing potential must agree to use effective contraception&#xD;
                  without interruption from 28 days prior to starting IP throughout 3 months after&#xD;
                  last dose of IP and have a negative serum pregnancy test (β -hCG) result at&#xD;
                  screening and agree to ongoing pregnancy testing during the course of the study,&#xD;
                  and after the end of study treatment. A second form of birth control is required&#xD;
                  even if she has had a tubal ligation.&#xD;
&#xD;
               -  Male patients must practice abstinence or agree to use a condom during sexual&#xD;
                  contact with a pregnant female or a female of childbearing potential while&#xD;
                  participating in the study and throughout 3 months after last dose of IP. A&#xD;
                  second form of birth control is required even if he has undergone a successful&#xD;
                  vasectomy.&#xD;
&#xD;
         13. Life expectancy of &gt;3 months, as determined by the investigator.&#xD;
&#xD;
         14. Ability to understand and sign informed consent.&#xD;
&#xD;
         15. Willingness and ability to comply with scheduled visits, laboratory tests, and other&#xD;
             study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe and uncontrolled allergic reactions to bevacizumab&#xD;
&#xD;
          2. Prior treatment with FOLFOX or bevacizumab within the preceding 4 weeks&#xD;
&#xD;
          3. Patients currently receiving or have received anticancer therapies within 4 weeks of&#xD;
             the start of study treatment (including chemotherapy, radiation therapy, antibody&#xD;
             based therapy, etc.)&#xD;
&#xD;
          4. Patients, who have had a major surgery or significant traumatic injury within 4 weeks&#xD;
             of start of study drug, patients who have not recovered from the side effects of any&#xD;
             major surgery (defined as requiring general anesthesia) or patients that may require&#xD;
             major surgery during the course of the study&#xD;
&#xD;
          5. Chronic treatment with systemic steroids or another immunosuppressive agent; topical&#xD;
             or inhaled corticosteroids are allowed&#xD;
&#xD;
          6. Recent infection requiring systemic anti-infective treatment that was completed ≤14&#xD;
             days prior to enrollment (with the exception of uncomplicated urinary tract infection&#xD;
             or upper respiratory tract infection).&#xD;
&#xD;
          7. Patients who have any severe and/or uncontrolled medical or psychiatric conditions or&#xD;
             other conditions that could affect their participation including:&#xD;
&#xD;
               1. Known active uncontrolled or symptomatic central nervous system (CNS) metastases.&#xD;
                  A patient with controlled and asymptomatic CNS metastases may participate in this&#xD;
                  study. As such, the patient must have completed any prior treatment for CNS&#xD;
                  metastases ≥28 days (including radiotherapy and/or surgery) prior to start of&#xD;
                  treatment in this study and should not be receiving chronic corticosteroid&#xD;
                  therapy for the CNS metastases.&#xD;
&#xD;
               2. Unstable angina pectoris, symptomatic congestive heart failure, myocardial&#xD;
                  infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac&#xD;
                  arrhythmia or any other clinically significant cardiac disease&#xD;
&#xD;
               3. Pre-existing severely impaired lung function as defined as spirometry and DLCO&#xD;
                  that is 50% of the normal predicted value and/or O2 saturation that is 88% or&#xD;
                  less at rest on room air (Note: spirometry and PFTs not required to be performed&#xD;
                  unless clinically indicated).&#xD;
&#xD;
               4. Uncontrolled diabetes as defined by fasting serum glucose &gt;1.5x ULN or by HbA1c&#xD;
                  &gt;8% despite adequate therapy.&#xD;
&#xD;
               5. Any active (acute or chronic) or uncontrolled infection/ disorders.&#xD;
&#xD;
               6. Nonmalignant medical illnesses that are uncontrolled or whose control may be&#xD;
                  jeopardized by the treatment with the study therapy. Note, controlled&#xD;
                  non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental&#xD;
                  prostate cancer, or other adequately treated carcinoma-in-situ may be eligible,&#xD;
                  after documented discussion with the sponsor / medical monitor.&#xD;
&#xD;
               7. Known liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh&#xD;
                  class C).&#xD;
&#xD;
          8. Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary&#xD;
             hypertension.&#xD;
&#xD;
          9. A known history of HIV seropositivity.&#xD;
&#xD;
         10. Active Hepatitis B or Hepatitis C. Note: A detailed assessment of Hepatitis B/C&#xD;
             medical history and risk factors must be done at screening for all patients. HBV DNA&#xD;
             and HCV RNA PCR testing are required at screening for all patients with a positive&#xD;
             medical history based on risk factors and/or confirmation of prior HBV/HCV infection.&#xD;
&#xD;
         11. Patients with an active bleeding diathesis or on oral anti-vitamin K medication&#xD;
             (except low dose Coumadin).&#xD;
&#xD;
         12. Use of strong inhibitors and inducers of CYP3A4 within the 14 days prior to receiving&#xD;
             the first dose of ABI-009. Additionally, use of any known CYP3A4 substrates with&#xD;
             narrow therapeutic window (such as fentanyl, alfentanil, astemizole, cisapride,&#xD;
             dihydroergotamine, pimozide, quinidine, terfanide) within the 14 days prior to&#xD;
             receiving the first dose of ABI-009.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Berta Grigorian</last_name>
    <phone>818-416-8378</phone>
    <email>bgrigorian@aadibio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joyce Schaffer, MSN RN AOCNS</last_name>
      <phone>480-323-1791</phone>
      <email>clinicaltrials@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Woolery</last_name>
      <phone>504-842-0275</phone>
      <email>Amanda.woolery@ochsner.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Arlene SJ. Ramirez, RN, OCN</last_name>
      <phone>702-952-3406</phone>
      <email>anaarlene.ramirez@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System/Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Ginder</last_name>
      <phone>973-971-6608</phone>
      <email>Nancy.ginder@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Preethi Ravindranathan</last_name>
      <phone>214-820-8685</phone>
      <email>Preethi.Ravindranathan@BSWHealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance/University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GI Research</last_name>
      <phone>206-606-6405</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 8, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2018</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

